Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
For patients with breast cancer, it's important to find any remaining cancer cells after they've had their main treatment. Even a few cells, called minimal residual disease (MRD), can lead to the cancer coming back later. A way to find these cells is by looking for tiny bits of cancer DNA that are shed into the blood. This is called circulating tumor DNA (ctDNA). A simple blood test, often called a liquid biopsy, can detect this ctDNA. This research aims to see if finding this cancer DNA in the blood can help predict if a patient's cancer will return. It also may help find out if the treatment is working. Ultimately, the results of this research may help doctors better manage breast cancer and develop new and improved tests and treatments.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Chęć i możliwość udziału w badaniu oraz pobrania próbek biologicznych
- •Chęć i możliwość podpisania świadomej zgody
- •Rozpoznanie raka piersi
- •Rak piersi typu HR+ HER2- na etapie II-III, wysokie ryzyko wznowy (4+ węzły chłonne lub 1-3 węzły z gradem 3 lub guzem ≥5cm)
- •Rak piersi typu HER2+ na etapie II-III (niezależnie od statusu HR)
- •Rak piersi potrójnie ujemny na etapie I-III
- •Przebyta operacja z zamiarem wyleczenia bez oznak choroby
- •Brak oznak choroby co najmniej 5 lat od diagnozy
✗ Disqualifies
- •Niemożliwość lub brak chęci do stosowania się do procedur badania
- •Aktywny nowotwór złośliwy w innej lokalizacji
- •Rozpoznanie innego nowotworu w ciągu 3 lat od diagnozy raka piersi (z wyjątkiem DCIS)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 99 Years
- Last updated (source)
- June 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (14)
Birmingham Hematology Associates
Birmingham, United States
PIH Health Whittier Hospital
Whittier, United States
Cleveland Clinic Florida
Weston, United States
Southern Illinois Hospital Services
Carbondale, United States
Cancer Care Specialist of Illinois
O'Fallon, United States
Goshen Center for Cancer Care
Goshen, United States
Trinity Health
Ann Arbor, United States
Oncology Hematology Associates
Springfield, United States
Cancer Care Specialist of Reno
Reno, United States
Summit Medical Group
Florham Park, United States
University of Cincinnati Medical Center
Cincinnati, United States
Nashville General
Nashville, United States
Cancer Care Northwest
Spokane Valley, United States
Gunderson Health
La Crosse, United States
Trial contact
GEMINI Breast Clinical Study Manager
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.